Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

UniQure's Huntington's Gene Therapy Shows Promise, but Experts Urge Caution

UniQure's Huntington's Gene Therapy Shows Promise, but Experts Urge Caution

Dutch biotech company uniQure has reported encouraging three-year data from its gene therapy trial for Huntington's disease, offering new hope to patients and families affected by this devastating neurodegenerative condition. However, some experts caution against creating unrealistic expectations at this stage of clinical development.

NoahAI News10/27/2025
Novartis Makes $12B Acquisition of Avidity Biosciences, Bolstering Neuromuscular Pipeline

Novartis Makes $12B Acquisition of Avidity Biosciences, Bolstering Neuromuscular Pipeline

Novartis has announced a major acquisition deal, agreeing to purchase Avidity Biosciences for approximately $12 billion. The transaction, which is expected to close in the first half of 2026, marks a significant investment in RNA-based therapies for neuromuscular diseases and represents one of the largest pharmaceutical deals of the year.

NoahAI News10/27/2025
Biogen Expands Immunology Pipeline with $1B Deal for Vanqua's C5aR1 Antagonist

Biogen Expands Immunology Pipeline with $1B Deal for Vanqua's C5aR1 Antagonist

Biogen has significantly bolstered its immunology portfolio by acquiring worldwide rights to Vanqua Bio's preclinical oral C5aR1 antagonist in a deal worth up to $1.06 billion. The agreement, announced on Friday, October 24, 2025, marks Biogen's first pipeline acquisition of the year and underscores the company's commitment to expanding its presence in immunological diseases.

NoahAI News10/25/2025
43rd Annual J.P. Morgan Healthcare Conference Set to Shape Industry Trends in 2025

43rd Annual J.P. Morgan Healthcare Conference Set to Shape Industry Trends in 2025

The 43rd Annual J.P. Morgan Healthcare Conference, slated for January 13-16, 2025, in San Francisco, California, is poised to be a pivotal event for the pharmaceutical and healthcare industries. This exclusive, invitation-only symposium will bring together global industry leaders, emerging fast-growth companies, innovative technology creators, and key members of the investment community.

NoahAI News10/25/2025
Eli Lilly Acquires Adverum Biotechnologies, Expanding Gene Therapy Portfolio

Eli Lilly Acquires Adverum Biotechnologies, Expanding Gene Therapy Portfolio

Eli Lilly and Company has announced the acquisition of Adverum Biotechnologies in a deal valued at up to $261.7 million, marking a significant expansion of Lilly's gene therapy pipeline. The acquisition centers on Adverum's lead program, Ixo-vec, a potential one-time gene therapy for wet age-related macular degeneration (wAMD) currently in Phase III clinical trials.

NoahAI News10/25/2025
GSK's Blenrep Makes Comeback with FDA Approval for Multiple Myeloma

GSK's Blenrep Makes Comeback with FDA Approval for Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has approved the return of GSK's multiple myeloma drug Blenrep, marking a significant turnaround for the once-withdrawn medication. The approval comes with a more limited label than initially anticipated, positioning Blenrep as a combination treatment for patients who have received at least two prior lines of therapy.

NoahAI News10/25/2025
Hyro Secures $45M in Growth Funding to Expand AI Agents in Healthcare

Hyro Secures $45M in Growth Funding to Expand AI Agents in Healthcare

Hyro, an artificial intelligence company focused on healthcare, has successfully raised $45 million in a strategic growth round, positioning itself as the "Responsible AI Agent Platform" for the industry. This latest funding nearly doubles the company's total capital raised to date and significantly increases its valuation.

NoahAI News10/25/2025
Accuray Announces New CEO and Transformation Plan Amid Financial Challenges

Accuray Announces New CEO and Transformation Plan Amid Financial Challenges

Accuray, a leading radiotherapy systems manufacturer, has unveiled significant changes in its leadership and strategic direction. The company has appointed Steve La Neve as its new CEO and launched a comprehensive transformation plan aimed at improving competitiveness and driving sustainable growth.

NoahAI News10/25/2025
Sanofi Reports Decline in Vaccine Sales Amid Shifting Immunization Landscape

Sanofi Reports Decline in Vaccine Sales Amid Shifting Immunization Landscape

French pharmaceutical giant Sanofi has reported a significant decrease in vaccine sales for the third quarter of 2025, citing slower-than-usual uptake of flu shots in the United States and increased price competition in Germany. Despite this setback, the company's overall revenue saw a modest increase, buoyed by strong performance in other key areas.

NoahAI News10/25/2025
Sanofi's Dupixent Soars to New Heights, Offsetting Vaccine Sales Decline

Sanofi's Dupixent Soars to New Heights, Offsetting Vaccine Sales Decline

Sanofi's blockbuster drug Dupixent has achieved a significant milestone, with quarterly sales surpassing €4 billion for the first time. This remarkable performance has helped the French pharmaceutical giant overcome a notable decline in vaccine sales, highlighting the drug's growing importance in Sanofi's portfolio.

NoahAI News10/25/2025
Teladoc CFO Mala Murthy to Step Down Amid Positive Q3 Results

Teladoc CFO Mala Murthy to Step Down Amid Positive Q3 Results

Teladoc Health, a leading telehealth company, announced on Thursday that Chief Financial Officer Mala Murthy will be stepping down from her role effective November 21. The announcement comes as the company released preliminary third-quarter financial results that surpassed investor expectations.

NoahAI News10/25/2025
Bayer's Lynkuet Gains FDA Approval, Expanding Nonhormonal Menopause Treatment Options

Bayer's Lynkuet Gains FDA Approval, Expanding Nonhormonal Menopause Treatment Options

Bayer has secured FDA approval for Lynkuet (elinzanetant), a novel nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause. This approval marks a significant expansion in the limited arsenal of nonhormonal options available to menopausal women in the United States.

NoahAI News10/25/2025
«1...789...67»